Last reviewed · How we verify
Captopril Test Dose and Trandolapril
Captopril and Trandolapril inhibit the angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and leading to vasodilation and decreased blood pressure.
Captopril and Trandolapril are both angiotensin-converting enzyme (ACE) inhibitors used primarily for the treatment of hypertension and heart failure. Captopril was one of the first ACE inhibitors to be developed and has been widely used since its approval in the 1980s. Trandolapril, a more recent addition, is known for its longer half-life and once-daily dosing. Both drugs work by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. Despite their effectiveness, they come with a range of side effects, including cough, hyperkalemia, and renal impairment. The drugs are not recommended for use in pregnant women due to potential fetal harm.
At a glance
| Generic name | Captopril Test Dose and Trandolapril |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Angiotensin-converting enzyme (ACE) inhibitors |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Mechanism of action
By blocking the conversion of angiotensin I to angiotensin II, these drugs reduce the vasoconstrictive and aldosterone-stimulating effects of angiotensin II, resulting in lower blood pressure and reduced workload on the heart.
Approved indications
Boxed warnings
- Fetal Toxicity
Common side effects
- Cough
- Hyperkalemia
- Renal Impairment
- Dizziness
- Fatigue
Drug interactions
- Potassium-sparing diuretics (e.g., spironolactone, triamterene)
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Lithium
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Acute Haemodynamic Effects of Treatment With Angiotensin Converting Enzyme (ACE)-Inhibitors in Patients With Symptomatic Aortic Stenosis (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US4374829 | ||
| US5260312 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Captopril Test Dose and Trandolapril CI brief — competitive landscape report
- Captopril Test Dose and Trandolapril updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI